Genmab — Oktober 2018
-
Tjah...det bliver nok ikke i dag vi får MAIA headlines..:-(
-
Interessant eksempel (15:45). I teorien kunne noget lignende jo godt være tilfældet i Maia. Altså at event raten pludselig aftager, fordi patienter med gavn af behandlingen vedbliver med det i lang tid, så det trækker ud (og så de sande resultater viser sig sent)
-
Jo, det er bare et ret bemærkelsesværdigt eksempel. Nyt: https://clinicaltrials.gov/ct2/show/NCT03697655?term=daratumumab&rank=15 Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)
-
Også fra i dag A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma https://clinicaltrials.gov/ct2/show/NCT03697629?term=daratumumab&draw=3&rank=3
-
EL : is this you ?https://twitter.com/EgidiusLambrech
-

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
